Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro

European Journal of Endocrinology

Volumn 141, Issue 4, 1999, Pages 396-408

  Florio, Tullio ^a,d,e   Thellung, Stefano ^a,b   Arena, Sara ^a,b   Corsaro, Alessandro ^a,b   Spaziante, Renato ^b   Gussoni, Gualberto ^c   Acuto, Giancarlo ^c   Giusti, Massimo ^d   Giordano, Giulio ^d   Schettini, Gennaro ^a,b,d,f  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c IPSEN   (France)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CALCIUM CHANNEL; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN TYROSINE PHOSPHATASE; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; DEPOLARIZATION; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADENOMA; CALCIUM CHANNELS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MEMBRANE POTENTIALS; MIDDLE AGED; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 0032706121     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1410396     Document Type: Article

References (51)

1. Gittoes NJL. Current perspective on the pathogenesis of clinically non-functioning pituitary tumors. Journal of Endocrinology 1998 157 177-186.
2. Black PM, Hsu DW, Klibanski A, Jameson JL, Ridgway EC, Hedley-Whyte ET et al. Hormone production in clinically non-functioning pituitary adenomas. Journal of Neurosurgery 1987 66 244-250.
3. Kontogeorgos G, Horvat E, Kovacs K, Killinger DW & Smyth HS. Null cell adenoma of the pituitary with features of plurihormonally and plurimorphous differentiation. Archives of Pathology and Laboratory Medicine 1991 115 61-64.
4. Florio T & Schettini G. Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors. Journal of Molecular Endocrinology 1996 17 89-100.
5. Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JGM & Lamberts SWJ. Somatostatin receptors in human endocrine tumors. Cancer Research 1987 47 551-558.
6. Dy DY, Whitehead RH & Morris DL. SMS 201-995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Research 1992 52 917-923.
7. Florio T, Scorziello A, Fattore M, D'Alto V, Salzano S, Rossi G et al. Somatostatin inhibits PC C13 thyroid cell proliferation through the modulation of phosphotyrosine phosphatase activity. Journal of Biological Chemistry 1996 271 6129-6136.
8. Prévost G, Foehrl E, Thomas F, Pihan I, Veber N, Starzec A et al. Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM2 3014. Endocrinology 1991 29 323-329.
9. Taylor JE, Moreau J-P, Baptiste L & Moody TW. Octapeptide analogues of somatostatin inhibit the clonal growth and vasoactive intestinal peptide-stimulated cyclic AMP formation in human small cell lung cancer cells. Peptides 1990 12 839-843.
10. Liebow C, Lee MT, Kamer AR & Schally AV. Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the USA 1991 88 2244-2248.
11. Tsuzaki S & Moses AC. Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells. Endocrinology 1990 126 3131-3138.
12. Buscail L, Delesque N, Estéve J-P, Saint-Laurent N, Prats H & Clerc P et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proceedings of the National Academy of Sciences of the USA 1994 91 2315-2319.
13. Florio T, Rim C, Hershberger RE, Loda M & Stork PJS. The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Molecular Endocrinology 1994 8 1289-1297.
14. Lee MT, Liebow C, Kamer AR & Schally AV. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proceedings of the National Academy of Sciences of the USA 1991 88 1656-1600.
15. Pan MG, Florio T & Stork PJS. G protein activation of a hormone-stimulated protein-tyrosine phosphatase in human tumor cells. Science 1992 256 1215-1217.
16. Giustina A & Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews 1998 19 717-797.
17. Bruno JF, Xu Y, Song J & Berelowitz M. Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology 1993 133 2561-2567.
18. Kumar U, Laird D, Srikant CB, Escher E & Patel YC. Expression of the five somatostatin receptors (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-label immunofluorescence confocal microscopy. Endocrinology 1997 138 4473-4476.
19. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT & Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1995 80 1386-1392.
20. Panetta R & Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sciences 1995 56 333-342.
21. Shimon I & Melmed S. Structure and function of somatostatin receptors in growth hormone control. Journal of Endocrinology 1997 155 S3-S6.
22. De Bruin TWA, Kwekkeboom DJ, Van't Verlaat JW, Reubi JC, Krenning EP & Lamberts SWJ. Clinically non-functioning pituitary adenoma and octreotide response to long term treatment and studies in vitro. Journal of Clinical Endocrinology and Metabolism 1992 75 1310-1317.
23. Katznelson L, Oppenheim DS, Coughlin JF, Kliman B, Schoenfeld DA & Klibanski A. Chronic somatostatin analog administration in patients with α-subunit-secreting pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1992 75 1318-1325.
24. Warnet A, Harris AG, Renard E, Martin D, James-Deidier A & Chaumet-Riffaud P. French Multicenter Octreotide Study Group. A prospective trial of octreotide in 24 patients with visual defects caused by non-functioning and gonadotropin-secreting pituitary adenomas. Neurosurgery 1997 41 786-797.
25. Billestrup N, Swanson LW & Vale W. Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proceedings of the National Academy of Sciences of the USA 1986 83 6854-6857.
26. Renner U, Mojto J, Lange M, Albrecht Muller O, von Werder K & Stalla GK. Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 1994 130 80-91.
27. Chomczynski P & Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 1987 162 156-159.
28. Florio T, Pan MG, Newman B, Hershberger RE, Civelli O & Stork PJS. Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity. Journal of Biological Chemistry 1992 267 24169-24172.
29. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Analytical Biochemistry 1976 72 248-254.
30. Dunphy WG & Kumagai A. The cdc25 protein contains an intrinsic phosphatase activity. Cell 1991 67 189-196.
31. Florio T, Grimaldi M, Scorziello A, Salmona M, Bugiani O, Tagliavini F et al. Intracellular calcium rise through the L-type calcium channel, as molecular mechanism for prion protein fragment 106-126-induced astroglial proliferation. Biochemical and Biophysical Research Communications 1996 228 397-405.
32. Grynkiewicz G, Poenie M & Tsien RY. A new generation of calcium indicators with greatly improved fluorescence properties. Journal of Biological Chemistry 1985 260 3440-3450.
33. Swarup G, Cohen S & Garbers DL. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochemical and Biophysical Research Communications 1982 107 1104-1109.
34. Lamberts SWJ, Krenning EP & Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews 1991 12 450-482.
35. Jones TH, Suliman M & Justice SK. Effects of interleukin 6 on thymidine uptake in human pituitary adenoma cells. Abstracts of the IV European Congress of Endocrinology, Seville, Spain, 9-13 May 1998, OR9-6.
36. Alvaro V, Turaine P, Raisman Vozari R, Bai-Grenier F, Birman P & Joubert D. Protein kinase C activity and expression in normal and adenomatous human pituitaries. International Journal of Cancer 1992 50 724-730.
37. Hamilton HB, Hinton DR, Law RE, Gopalakrishna R, Su YZ, Chen ZH et al. Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutical application. Journal of Neurosurgery 1996 85 329-334.
38. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR & Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumors. Nature 1989 340 692-696.
39. Tordjman K, Stern N, Ouaknine G, Yossiphov Y, Razon N, Nordenskjold M et al. Activating mutations of the Gs alpha gene in non-functioning pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1993 77 765-769.
40. Williamson EA, Daniels M, Foster S, Kelly WF, Kendall-Taylor P & Harris PE. Gs alpha and Gi2 mutations in clinically non-functioning pituitary tumors. Clinical Endocrinology 1993 41 815-820.
41. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H & Srikant CB. The somatostatin receptor family. Life Sciences 1995 57 1249-1265.
42. ++ channels in the beta cell. Journal of Biological Chemistry 1991 266 837-843.
43. Reiss N, Llevi LN, Shacham S, Harris D, Seger R & Naor Z. Mechanism of mitogen activated protein kinase activation by gonadotropin-releasing hormone in the pituitary αT3-1 cell line: differential roles of calcium and protein kinase C. Endocrinology 1997 138 1673-1682.
44. Rosen LB, Ginty DD, Weber MJ & Greenberg ME. Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of ras. Neuron 1994 12 1207-1221.
45. ++ current in the pituitary cell line AtT20. Neuroscience 1996 71 1073-1081.
46. Chen L, Fitzpatrick VD, Vandlen RL & Tashjian AH Jr. Both overlapping and distinct signaling pathways for somatostatin receptor subtypes SSTR1 and SSTR2 in pituitary cells. Journal of Biological Chemistry 1997 272 18666-18672.
47. ++ influx. Endocrinology 1991 128 583-591.
48. Chen ZP, Xu S, Lightman S, Hall L & Levy A. Intracellular calcium ion responses to somatostatin in cells from human somatotrophs adenomas. Clinical Endocrinology 1997 46 45-53.
49. Reardon DR, Dent P, Wood SL, Kong T & Sturgill TW. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from rastransformed NIH3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Molecular Endocrinology 1997 11 1062-1069.
50. Florio T, Scorziello A, Thellung S, Salzano S, Berlingieri MT, Fusco A et al. Oncogene transformation of PC C13 clonal thyroid cell line that induces an autonomous pattern of proliferation that correlates with loss of basal and stimulated phosphotyrosine phosphatase activity. Endocrinology 1997 138 3756-3763.
51. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proceedings of the National Academy of Sciences of the USA 1995 92 1580-1584.